INTRODUCTION {#sec1-1}
============

Colorectal cancer is one of the most important causes of morbidity and mortality in the world.\[[@ref1][@ref2]\] More than 9% of all cancer incidences are belonged to it.\[[@ref3]\] Colorectal cancer is the fourth most frequent cause of death and third most common cancer worldwide that is more widespread in developed countries.\[[@ref4][@ref5]\] Nowadays, following the response to therapy in patients with cancer, who receives chemotherapy, is an important issue. Toward this end, various biological markers have been introduced as potential biomarkers in colorectal cancer cases. Carcinoembryonic antigen (CEA) is a glycoprotein that would be generated in gastrointestinal tissue at some stage in fetal maturity and plays some roles in cell adhesion. Inasmuch as CEA exists only at scarce levels in the blood of healthy adults, and arise only in some kinds of cancer, usually would be applied as a tumor marker in clinical experiments.\[[@ref6][@ref7][@ref8][@ref9]\] The specificity of CEA is usually associated with the site of metastases. In metastatic colorectal cancer of lungs, the CEA elevation is not sufficiently enough and also could be significantly affected by chemotherapy; totally, cures ascribable to CEA monitoring are commonly scarce.\[[@ref10][@ref11]\] Despite the aforesaid limitations, CEA is currently used as a serological diagnostic factor. In some literature, it has been suggested that tissue inhibitor of metalloproteinase-1 (TIMP-1) plays a particular role in cancer promotion.\[[@ref12]\] They have expressed that there is an association between high plasma TIMP-1 levels and low prognosis of colorectal cancer patients.\[[@ref13][@ref14][@ref15]\] In a study, 45% increase in plasma TIMP-1 levels significantly decreased the overall survival, while in individuals who had TIMP-1 plasma reduction from the baseline level, have had superior overall survival.\[[@ref16]\] Overall, in the setting of improving the diagnostic power for following the response to chemotherapy in patients with metastatic colorectal cancer, since CEA assay is not a self-determining test and also has considerable rates of false positivity and false negativity monitoring, its accompany with another biomarker such as TIMP-1 sounds logical. In this regard, the present investigation tries to compare the effect of repeated measurement of CEA and TIMP-1 plasma levels in a follow-up response to chemotherapy treatment in patients with unresectable metastatic colorectal cancer by surgery.

MATERIALS AND METHODS {#sec1-2}
=====================

All consecutive patients with rectal adenocarcinoma who referred to Sayed Al-Shohada Medical Center in Isfahan, Iran, Between September 2013 and March 2014, were scheduled to enroll in the present study (30 consecutive patients with primary rectal adenocarcinoma). Patients between 18 and 75 years old in both genders that had evidence of distant metastasis with no previous or concurrent other malignancy and did not receive previous or concurrent chemotherapy were eligible. Also patients with current infection, severe uncontrolled diabetes, central nervous system metastases, unresolved bowel obstruction, uncontrolled inflammatory bowel disease, current history of chronic diarrhea, or any other serious medical condition or that hindered treatment with chemotherapy were excluded from the study. The internal board and ethics committee of the Isfahan University of Medical Sciences investigated and approved this study. All of the participants were counseled, and a written informed consent was obtained from all of them.

Based on the physician\'s judgment and good clinical practice at the time of treatment, patients in the study received two cycles of standard chemotherapy (3 weeks in every cycle). Before and after the first and the second cycles of chemotherapy blood samples were collected from an antecubital vein using a light tourniquet. Samples were drawn into tubes with ethylenediaminetetraacetic acid as an anticoagulant for plasma and without additives for serum. Then the supernatants were separated from the blood cells at room temperature and stored at −80°C until samples had been collected from the patients and weekly were analyzed.

The collected information included age, gender, serum level of CEA and TIMP-1, and also a response to chemotherapy. Plasma level of TIMP-1 in the cytosols was measured using an established, validated in-house enzyme-linked immunosorbent assay (ELISA). Plasma level of CEA analyses was measured using the principle of solid-phase ELISA. Level of CEA and TIMP-1 were assessed before and after two cycles of chemotherapy. Furthermore, patients underwent computed tomography scan to assess response to chemotherapy, which were evaluated by the same radiologist and were graded according to the response evaluation criteria in solid tumors. In this study, disappearance of all target and nontarget lesions and reduction in the longest diameters of target lesions lower than 10 mm was defined as a response to chemotherapy and all other condition defined as no response to chemotherapy.

SPSS version 20 (SPSS Inc.; Chicago, IL, USA) was used to managed and analyzed the data. Descriptive data are reported as mean ± standard deviation or number (percent) as appropriate. Due to a small number of samples Mann-Whitney test and Wilcoxon, where appropriate, were used to compare continues data between patients with successful or unsuccessful chemotherapy. For serum level of CEA and TIMP, a receiver operating characteristic (ROC) curve analysis was used to establish the cut-off values that optimized the prediction of response to chemotherapy. Sensitivity, specificity, and areas under the ROC curves (AUC) were then calculated for baseline level of CEA and TIMP. All probability tests used were two-tailed, and alpha was set at 5%.

RESULTS {#sec1-3}
=======

During two cycles of chemotherapy five patients were excluded from the study and 25 patients were followed to assess chemotherapy response. The mean age of the studied patients was 52.7 ± 7.5 years, 12 patients (48%) were male and 13 patients (52%) were female.

Response to chemotherapy after two cycles was 80% (20 out of 25 patients), and 20% (5 of 25) did not response to chemotherapy. [Table 1](#T1){ref-type="table"} shows the level of CEA and TIMP in studies patients by response to chemotherapy. As shown in first cycle of chemotherapy, the level of CEA and TIMP before and after treatment was not significantly different between patients who response to chemotherapy compared to whom did not response to chemotherapy (*P* \> 0.05). In patients who responded to chemotherapy, the level of CEA and TIMP after treatment was decreased compared to before treatment but these were no statistically significant (*P* \> 0.05). In patients who did not respond level of CEA and TIMP after treatment was increased compared to before treatment which these were no statistically significant (*P* \> 0.05). In addition, after second cycle of chemotherapy, the level of CEA before and after treatment between and within patients who responded to chemotherapy and who did not response to chemotherapy was not significantly different (*P* \> 0.05). In patients who responded to chemotherapy level of TIMP after treatment was significantly decreased compared to before treatment (*P* \< 0.0001). Before and after treatment in patients who responded to chemotherapy the level of TIMP was significantly lower than who did not response to chemotherapy (*P* \< 0.05).
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CEA and TIMP in studies patients by response to chemotherapy
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Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} show the results on a comparison of the trend of level of CEA and TIMP between patients who responded to treatment and who did not response to treatment. The level of CEA in patients who responded to treatment was decreased during two cycles of chemotherapy but in whom did not response to treatment was increased during chemotherapy, the difference in the trend of CEA was not statistically significant between patients (*P* = 0.37) \[[Figure 1](#F1){ref-type="fig"}\]. The trend of the level of TIMP in patients who responded to treatment decreased and in whom did not response to treatment was increased during two cycles of chemotherapy which was statistically significant (*P* = 0.025) \[[Figure 2](#F2){ref-type="fig"}\].

![Comparison of carcinoembryonic antigen (CEA) between patients who response to treatment and who did not response to treatment. The difference of the trend of CEA was not statistically significant between patients (*P* = 0.37)](JRMS-19-1129-g002){#F1}

![Comparison of tissue inhibitor of metalloproteinase-1 (TIMP) between patients who response to treatment and who did not response to treatment. The difference of the trend of TIMP was statistically significant between patients (*P* = 0.025)](JRMS-19-1129-g003){#F2}

To determine the critical values that could predict response to chemotherapy, ROC curves were generated for baseline level of CEA and TIMP. The curve constructed for CEA was \>63 (sensitivity, 40, 95% confidential interval \[CI\], 6.5-84.6; and specificity, 90, 95% CI, 68.3-98.5; and AUC, 0.540, *P* = 0.79). The curve constructed for TIMP was TIMP ≤8823 (sensitivity, 80, 95% CI, 28.8-96.7; and specificity, 80, 95% CI, 56.3-94.1; and AUC, 0.680, *P* = 0.15). There was no significant relationship between the baseline level of CEA and TIMP with response to chemotherapy in obtained cut-off points \[[Figure 3](#F3){ref-type="fig"}\].

![Receiver operating characteristic curves for carcinoembryonic antigen (area under the curve, 0.540; standard error \[SE\], 0.15; *P* = 0.79) and tissue inhibitor of metalloproteinase-1 (area under the curve, 0.680; SE, 0.12; *P* = 0.15) for predicting response to treatment in patients with rectal adenocarcinoma underwent chemotherapy](JRMS-19-1129-g004){#F3}

DISCUSSION {#sec1-4}
==========

Efficient predictive biomarker should maintain patients from unsuccessful treatments and thereby from the unpleasant impacts caused by chemotherapy. Therefore, due to ameliorating the diagnostic power for following the response to chemotherapy in patients with metastatic colorectal cancer, present investigation compares the effect of repeated measurement of CEA and TIMP-1 plasma levels in a follow-up response to chemotherapy treatment, in patients with unresectable metastatic colorectal cancer by surgery.

Our investigation indicated that in patients who responded to chemotherapy, the level of TIMP-1, after treatment was significantly decreased compared to before treatment (*P* \< 0.0001). Meanwhile, the level of CEA before and after treatment between and within patients who responded to chemotherapy and who did not response to chemotherapy was not significantly different.

Our findings are keeping with an independent prospective validation study conducted by Birgisson *et al*. They expressed that there are a significant association among preoperative plasma TIMP-1 levels and survival of colorectal cancer cases. Our observation also indicated that the trend of TIMP-1 level in patients who responded to chemotherapy treatment decreased and in those cases that did not respond to treatment has increased during two cycles of chemotherapy. Another consistency between our results and theirs are relied on this fact that TIMP-1 provided stronger prognostic information than CEA.\[[@ref17]\] Although the level of CEA in patients who responded to treatment has decreased during two cycles of chemotherapy and in those who did not respond to treatment increased during chemotherapy, the difference in the trend of CEA was not statistically significant between patients. Reports have demonstrated that in colorectal cancer, breast cancer and lung cancer the TIMP-1 mRNA levels in tumor tissues are significantly associated with patient.\[[@ref18][@ref19][@ref20]\] The survival of colorectal cancer patients had a strong association with preoperative plasma TIMP-1 levels, so that higher plasma TIMP-1 levels was associated with poor outcome; in Holten-Andersen *et al*. study. They expressed plasma TIMP-1 as a strongly predictive biomarker in prognosis of colorectal cancer.\[[@ref15]\]

Studies conducted based on ELISA measurements of total TIMP-1 in tumor tissues that confirms our results are also suggests that increased plasma ratios of the TIMP-1 inhibitor are associated with shorter survival.\[[@ref21][@ref22][@ref23]\]

Several studies found that CEA serum level is an appropriate biomarker in chemotherapy monitoring.\[[@ref24][@ref25][@ref26]\]

Also in patients with unresectable metastasis of colorectal cancer, the CEA kinetic has been suggested as an accurate, easy, and noninvasive technique to recognize the disease progression.\[[@ref8]\] Taking these data together with the results of our screens, we could conclude that although the level of CEA was not statistically significant between patients; we should not neglect the fact that CEA in patients who responded to treatment decreased and in those who did not respond to treatment has increased during the chemotherapy.

In fact, one of the limitations that our study suffers from is few sample size that could effects on accurate estimation of biomarker positions that should be considered in future studies.

CONCLUSION {#sec1-5}
==========

The present investigation has identified a strong significant association between high plasma TIMP-1 levels and short survival in patients with colorectal cancer. In addition, results demonstrated that the TIMP-1 provides stronger prognostic information than CEA. Nonetheless, supplementary researches with more sample size are considered necessary to clarify the significance of TIMP-1 in cancer progression as well as the potential clinical use and its superiority over CEA.
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